Form 8-K - Current report:
SEC Accession No. 0001493152-25-004002
Filing Date
2025-01-28
Accepted
2025-01-28 16:51:45
Documents
16
Period of Report
2025-01-28
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42598
2 ex99-1.htm EX-99.1 17656
3 ex99-1_001.jpg GRAPHIC 2111
  Complete submission text file 0001493152-25-004002.txt   294922

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tvgn-20250128.xsd EX-101.SCH 3815
5 XBRL DEFINITION FILE tvgn-20250128_def.xml EX-101.DEF 30098
6 XBRL LABEL FILE tvgn-20250128_lab.xml EX-101.LAB 36844
7 XBRL PRESENTATION FILE tvgn-20250128_pre.xml EX-101.PRE 27121
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5977
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE 410 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE 410 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Filer) CIK: 0001860871 (see all company filings)

EIN.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41002 | Film No.: 25565112
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)